SE9602145D0 - New improved formulation for treatment of thromboembolism - Google Patents

New improved formulation for treatment of thromboembolism

Info

Publication number
SE9602145D0
SE9602145D0 SE9602145A SE9602145A SE9602145D0 SE 9602145 D0 SE9602145 D0 SE 9602145D0 SE 9602145 A SE9602145 A SE 9602145A SE 9602145 A SE9602145 A SE 9602145A SE 9602145 D0 SE9602145 D0 SE 9602145D0
Authority
SE
Sweden
Prior art keywords
treatment
thromboembolism
formulation
new improved
improved formulation
Prior art date
Application number
SE9602145A
Other languages
English (en)
Swedish (sv)
Inventor
Anna-Lena Ungell
Jan-Erik Loefroth
Lennart Lindfors
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9602145A priority Critical patent/SE9602145D0/xx
Publication of SE9602145D0 publication Critical patent/SE9602145D0/xx
Priority to IDP971453A priority patent/ID19472A/id
Priority to ARP970102135A priority patent/AR013569A1/es
Priority to ZA9704386A priority patent/ZA974386B/xx
Priority to AU31115/97A priority patent/AU722450B2/en
Priority to PCT/SE1997/000914 priority patent/WO1997045138A1/en
Priority to US08/894,615 priority patent/US6673365B1/en
Priority to DE69731981T priority patent/DE69731981T2/de
Priority to NZ332788A priority patent/NZ332788A/xx
Priority to JP09542227A priority patent/JP2000511526A/ja
Priority to CA002253410A priority patent/CA2253410A1/en
Priority to EP97926326A priority patent/EP1015022B1/de
Priority to AT97926326T priority patent/ATE284706T1/de
Priority to NO985558A priority patent/NO985558L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
SE9602145A 1996-05-31 1996-05-31 New improved formulation for treatment of thromboembolism SE9602145D0 (sv)

Priority Applications (14)

Application Number Priority Date Filing Date Title
SE9602145A SE9602145D0 (sv) 1996-05-31 1996-05-31 New improved formulation for treatment of thromboembolism
IDP971453A ID19472A (id) 1996-05-31 1997-05-01 Formulasi perbaikan baru untuk pengobatan tromboembolisme
ARP970102135A AR013569A1 (es) 1996-05-31 1997-05-20 Nueva formulacion mejorada para el tratamiento de la tromboembolia
ZA9704386A ZA974386B (en) 1996-05-31 1997-05-20 New formulation for treatment of thromboembolism.
AT97926326T ATE284706T1 (de) 1996-05-31 1997-05-28 Neue verbesserte formulierung zur behandlung von thromboembolismus
US08/894,615 US6673365B1 (en) 1996-05-31 1997-05-28 Formulation for treatment of thromboembolism
PCT/SE1997/000914 WO1997045138A1 (en) 1996-05-31 1997-05-28 New improved formulation for treatment of thromboembolism
AU31115/97A AU722450B2 (en) 1996-05-31 1997-05-28 New improved formulation for treatment of thromboembolism
DE69731981T DE69731981T2 (de) 1996-05-31 1997-05-28 Neue verbesserte formulierung zur behandlung von thromboembolismus
NZ332788A NZ332788A (en) 1996-05-31 1997-05-28 Composition for the treatment of thromboebolism
JP09542227A JP2000511526A (ja) 1996-05-31 1997-05-28 血栓症の処置のための新規改良組成物
CA002253410A CA2253410A1 (en) 1996-05-31 1997-05-28 New improved formulation for treatment of thromboembolism
EP97926326A EP1015022B1 (de) 1996-05-31 1997-05-28 Neue verbesserte formulierung zur behandlung von thromboembolismus
NO985558A NO985558L (no) 1996-05-31 1998-11-27 Ny forbedret formulering for behandling av tromboembolisme

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9602145A SE9602145D0 (sv) 1996-05-31 1996-05-31 New improved formulation for treatment of thromboembolism

Publications (1)

Publication Number Publication Date
SE9602145D0 true SE9602145D0 (sv) 1996-05-31

Family

ID=20402816

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9602145A SE9602145D0 (sv) 1996-05-31 1996-05-31 New improved formulation for treatment of thromboembolism

Country Status (14)

Country Link
US (1) US6673365B1 (de)
EP (1) EP1015022B1 (de)
JP (1) JP2000511526A (de)
AR (1) AR013569A1 (de)
AT (1) ATE284706T1 (de)
AU (1) AU722450B2 (de)
CA (1) CA2253410A1 (de)
DE (1) DE69731981T2 (de)
ID (1) ID19472A (de)
NO (1) NO985558L (de)
NZ (1) NZ332788A (de)
SE (1) SE9602145D0 (de)
WO (1) WO1997045138A1 (de)
ZA (1) ZA974386B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
SE0203349D0 (sv) * 2002-11-12 2002-11-12 Astrazeneca Ab New use
DK1569912T3 (en) 2002-12-03 2015-06-29 Pharmacyclics Inc 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464175A (en) * 1982-08-25 1984-08-07 Altman Alan R Multipurpose tamponade and thrombosclerotherapy tube
AU1629383A (en) * 1982-10-02 1984-04-05 Amano Seiyaku K.K. Earthworm tissue protease thrombolytic agents
EP0662826A1 (de) * 1992-10-02 1995-07-19 Pfizer Inc. Pharmazeutische zusammensetzungen enthaltend nichtionische tenside
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE9302135D0 (sv) * 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation

Also Published As

Publication number Publication date
AU722450B2 (en) 2000-08-03
US6673365B1 (en) 2004-01-06
AR013569A1 (es) 2001-01-10
EP1015022B1 (de) 2004-12-15
DE69731981D1 (de) 2005-01-20
ID19472A (id) 1998-07-16
CA2253410A1 (en) 1997-12-04
NO985558D0 (no) 1998-11-27
DE69731981T2 (de) 2005-12-22
JP2000511526A (ja) 2000-09-05
AU3111597A (en) 1998-01-05
ATE284706T1 (de) 2005-01-15
NO985558L (no) 1998-11-27
EP1015022A1 (de) 2000-07-05
ZA974386B (en) 1997-12-01
WO1997045138A1 (en) 1997-12-04
NZ332788A (en) 2000-05-26

Similar Documents

Publication Publication Date Title
SE9404196D0 (sv) New antithrombotic formulation
PT966447E (pt) Moleculas pequenas uteis no tratamento de doencas inflamatorias
NO20061736L (no) Krystallform av epotilon B
ATE305788T1 (de) (s,s)-reboxetin zur behandlung von inkontinenz
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
GB9818916D0 (en) Use
NO20075066L (no) Farmasoytisk sammensetning som inneholder isoflavoner
EA199800667A1 (ru) Новые фенантридины
NZ337211A (en) Method of treating inflammatory, HIV diseases by using peptidyl boronic acid ester and acid compounds as proteasome inhibitors
TR199802676A2 (xx) T�m�rlerin, t�m�rle ilgili hastal�klar�n ve ka�eksinin tedavisi ve �nlenmesi i�in y�ntem.
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
DE60310400D1 (de) Botulinustoxine zur behandlung von priapismus
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
FI103111B1 (fi) Menetelmä proteolyyttisen entsyymin inhibiittoreina käyttökelpoisten sakkariinijohdannaisten valmistamiseksi
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
DE69931938D1 (de) Verfahren zum sterilisieren von cyanoacrylatmischungen
SE9602145D0 (sv) New improved formulation for treatment of thromboembolism
MXPA02004699A (es) Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco.
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
NO970185L (no) Anvendelse av (S)-adenosyl-L-metionin (SAMe) og dets fysiologisk kompatible salter for behandling av reperfusjonsskade utlöst av temporær-fokal-ischemi
RU96119673A (ru) Способ лечения болевого синдрома
EA199800822A1 (ru) Способ лечения избыточной агрессии
NO981594L (no) Behandling av infeksjoner forÕrsaket av Helicobacter pylori
CO5170459A1 (es) Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos